

SPRING GROUP MEETING

# Seattle

# Gastrointestinal Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

# Gastrointestinal Committee

## Leadership

Chair: ..... Philip A. Philip, MD, PhD, FRCP  
 Vice-Chair: ..... Elena G. Chiorean, MD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Katherine A. Guthrie, PhD  
 ..... Sarah Colby, MS

## Scientific Leadership

Gastroesophageal: ..... Syma Iqbal, MD  
 ..... Zev A. Wainberg, MD  
 Pancreatic: ..... Davendra P.S. Sohal, MD  
 ..... Andrew M. Lowy, MD (Surgical representative)  
 Hepatobiliary: ..... Anthony B. El-Khoueiry, MD  
 ..... Rachna T. Shroff, MD  
 ..... Syed A. Ahmad, MD (Surgical representative)  
 Colon: ..... Marwan G. Fakih, MD  
 ..... Philip J. Gold, MD  
 ..... Sepideh Gholami, MD (Surgical representative)  
 Neuroendocrine Tumors: ..... Nageshwara Arvind Dasari, MD  
 ..... Jonathan R. Strosberg, MD  
 Ano-Rectal: ..... Lisa A. Kachnic, MD  
 ..... Hagen F. Kennecke, MD  
 Imaging: ..... Anthony F. Shields, MD, PhD  
 Pathology: ..... Mary Kay Washington, MD, PhD  
 Radiation Oncology: ..... Lisa A. Kachnic, MD  
 Surgery: ..... Stephen W. Behrman, MD  
 ..... Syed A. Ahmad, MD  
 ..... Flavio Rocha, MD  
 Translational Medicine: ..... Gabriel N. Duda, PhD, DMD  
 ..... Maheswari Senthil, MD

## Designates

Cancer Control Liaisons: ..... Jason A. Zell, DO (Prevention)  
 ..... Afsaneh Barzi, MD (CCD)  
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)  
 ..... Mohamed E. Salem, MD (Medical Oncology)  
 ..... Flavio Rocha, MD (Surgical)  
 ..... David Horowitz, MD (Radiation Oncology)  
 DEI Champion: ..... Colmar Figueroa-Moseley, PhD, MPH  
 ..... Rachael Ann Safyan, MD  
 Digital Engagement: ..... Heloisa Soares, MD, PhD  
 Veterans Affairs: ..... Rangaswamy Govindarajan, MD  
 Data Coordinators: ..... Alex Rangel, BS  
 ..... Brian Zeller  
 ..... Christine Magner

## Oncology Research Professionals:

CRA: ..... Michelle A. Springer, BA  
 Nurse: ..... TBD  
 Patient Advocate (Pancreatic): ..... Carole Seigel, MBA  
 Patient Advocate (Colon): ..... Florence Kurttila, MS  
 Pharmaceutical Science: ..... Jane E. Rogers, PharmD  
 ..... Safae Chouraichi, PharmD  
 Protocol Project Manager: ..... Andrea Garcia  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Friday, April 5, 2024 4:30 p.m. - 6:30 p.m.  
 Room: Columbia D (Level 3)

## Agenda

1. Welcome
2. Announcements & Introductions Philip Philip  
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa-  
Moseley, Carole Seigel, Florence Kurttila
4. SWOG Led Trials Updates
 

a. S1922	Michael Overman
b. S2001	Vincent Chung
c. S2104	Heloisa Soares/S. Ahmad
d. S2107	Van Morris
e. S2012	David Zhen/E. Gabriela Chiorean
f. S2303	Anwaar Saeed/Paul Oberstein
5. SWOG Co-Led Trials Updates
 

a. A022104	Arvind Dasari
b. A022001	Heloisa Soares
c. EA2192	Anup Kasi
d. NRG-GI004	Michael Overman
e. NRG-GI008	Christopher Lieu
f. CCTG NE1	Aman Chauhan
6. Anal and Rectal
 

a. Major recent clinical results	Hagen Kennecke, Lisa Kachnic
b. NCTN trials update	
c. Future SWOG plans	



# Gastrointestinal Committee

- |   |  |
|---|--|
| 7. Colon  | Marwan Fakhri, Philip Gold,<br>Sepideh Gholami |
| <ul style="list-style-type: none"> <li>a. Major recent clinical results</li> <li>b. NCTN trials update</li> <li>c. Future SWOG plans</li> </ul> |  |
| 8. Gastroesophageal   | Syma Iqbal, Zev Wainberg                       |
| <ul style="list-style-type: none"> <li>a. Major recent clinical results</li> <li>b. NCTN trials update</li> <li>c. Future SWOG plans</li> </ul> |  |
| 9. Hepatobiliary  | Anthony El-Khoueiry<br>Rachna Shroff           |
| <ul style="list-style-type: none"> <li>a. Major recent clinical results</li> <li>b. NCTN trials update</li> <li>c. Future SWOG plans</li> </ul> |  |
| 10. Neuroendocrine  | Jon Strosberg, Arvind Dasari                   |
| <ul style="list-style-type: none"> <li>a. Major recent clinical results</li> <li>b. NCTN trials update</li> <li>c. Future SWOG plans</li> </ul> |  |
| 11. Pancreatic  | Davendra Sohal, Andrew Lowy                    |
| <ul style="list-style-type: none"> <li>a. Major recent clinical results</li> <li>b. NCTN trials update</li> <li>c. Future SWOG plans</li> </ul> |  |
| 12. Discussion/Other business   |  |
| 13. Adjourn   |  |

## Gastroesophageal

### Active Studies

**S2303**, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS  $\geq$  1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)", Drs. Saeed and Oberstein. Activated: 3/15/24.

**CTSU/A022102**, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." Dr. Oberstein. Activated: 1/17/19.

**CTSU/EA2174**, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/2022.

**CTSU/EA2183**, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/2020.

**CTSU/NRG-GI006**, "Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer." Dr. Zhen. Activated: 3/16/19.

## Pancreatic

### Developing Studies

**SXXXX**, "Randomized Phase II Study of Second-Line Chemotherapy with or Without Panitumumab for Locally Advanced or Metastatic KRAS/ BRAFV600E Wild-Type Pancreatic Ductal Adenocarcinoma." Drs R. Safyan and EG Chiorean. Presented at Pancreas Cancer Task Force 02/2023.

### Active Studies

**S2001**, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

**CTSU/A021806**, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

**CTSU/A022106**, "Phase II/III Second-Line Nabplagem Vs. Nab-Paclitaxel/ Gemcitabine In Brca1/2 Or Palb2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." Dr. Greg Botta, Activated: 12/1/23.

**CTSU/EA2186**, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naive Metastatic Pancreatic Cancer (GIANT)." Dr. Zhen. Activated: 6/18/20.

**CTSU/EA2192**, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

**CTSU/EA2185**, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs." Dr. Pillarisetty. Activated: 01/16/2020.

## Neuroendocrine

### Active Studies

**S2104**, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine

# Gastrointestinal Committee

and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21.

**S2012**, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)" Activated Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/02/2021

**CTSU/A021602**, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18. Temporarily Closed to Accrual as of 08/07/2023

**CTSU/A021804**, A Prospective, Multi-institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma. Dr C. Lopez. Activated: 11/02/2020.

**CTSU/A021901**, Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors. Dr. Hendifar. Activated: 09/10/2021

**CTSU/A022001**, Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors. Dr. Soares. Activated: 03/16/2022

**CTSU/CCTG NE1**, Comparing retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment. Dr A. Chauhan. Activated: 06/14/2023.

## Colon/Small Bowel

### Developing Studies

**S2420**, "A Randomized Phase II Trial of Regorafenib, Ipilimumab, and Nivolumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Metastatic Colorectal Cancer Without Liver Metastases", Dr. Fakhri. Approved by SWOG Executive Committee on 12/22/23

**XXXX**, PreOpEraTive Immunotherapy and Chemotherapy for Colon Cancer (POETIC) Drs Krishnamurthy and Senthil. Presented at Colon Cancer Task Force 09/2023.

### Active Studies

**S2107**, Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer. Dr. V. Morris. Activated: 6/06/2022.

**S1922**, Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma. Dr. M. Overman. Activated: 12/16/2019.

**CTSU/A022004**, Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer. Drs. Krishnamurthi, Subramanyan. Activated: 05/30/2023.

**CTSU/A022101**, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)" Dr. S. Gholami. Activated: 1/10/23.

**CTSU/NRG-GI004/S1610**, Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer. Dr. M. Overman. Activated: 11/07/2017.

**CTSU/NRG-GI008**, Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Dr. C. Lieu. Activated 03/10/2022.

## Rectal/Anal

### Active Studies

**CTSU/A022104**, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer" Activated 11/9/2022. SWOG Champion: A. Dasari

**CTSU/EA2176**, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

**CTSU/EA2182**, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Dr. Murphy. Activated: 11/12/19.

## Hepatobiliary

### Developing Studies

**XXXX**, Randomized Phase 2 trial of Liposomal Irinotecan, Fluorouracil, Leucovorin, and Onvansertib in Second-Line Treatment of KRAS-Mutated Advanced Biliary Tract Cancer. Dr. R. Kim. Presented at the Hepatobiliary Task Force 06/2023.

# Gastrointestinal Committee

## Active Studies

**CTSU/NRG-GI003**, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

**CTSU/EA2197**, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

**CTSU/EA2205**, A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma. Activated: 02/11/2022

## Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

## Published/Accepted Manuscripts

**S1505** Intra-tumoral cell neighborhoods coordinate outcomes in pancreatic ductal adenocarcinoma. Wattenberg M, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Beg M, Wang-Gillam A, Wade J, Guthrie K, Chiorean EG, Ahmad S, Lowy A, Philip PA, Sohal D, Beatty G. *Gastroenterology* Jan 18:S0016-5085(24)00049-0. doi: 10.1053/j.gastro.2024.01.013. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38244727/>

**S1505** Body Composition Measurements and Clinical Outcomes in Patients with Resectable Pancreatic Adenocarcinoma: Analysis from SWOG S1505 [Brief Report]. Sohal D, Boutin R, Lenchik L, Kim J, Beg S, Wang-Gillam A, Wade J, Guthrie KA, Chiorean E, Ahmad S, Lowy A, Philip P, Chang V. Accepted 2024.

**S1505** Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Cloyd J, Colby S, Guthrie KA, Lowy A, Chiorean E, Philip P, Sohal D, Ahmad S. Accepted 2023.

**S2104** Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors [Research Letter]. Ryan C, Saif A, Rocha F, Philip P, Hernandez J, Ahmad S, Soares H. *Ann Surg Oncol*. Mar;30(3):1302-1304, 2023. <https://pubmed.ncbi.nlm.nih.gov/36474095/>

**C/S80405** Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Arai H, Yang Y, Millstein J, Denda T, Ou F, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Zhang W, Goldberg R, Hall M, Scott A, Hwang J, Lou E, Weinberg B, Marshall J, Goel S, Xiu J, Korn M, Venook A, Sunakawa Y, Lenz H-J. *Eur J Cancer* Feb 10:201:113914. doi:10.1016/j.ejca.2024.113914. Online ahead of print, 2024.. <https://pubmed.ncbi.nlm.nih.gov/38359495/>

**C80802** CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma. Abou-Alfa G, Geyer S, Nixon A, Innocenti F, Shi Q, Jacobson S, El Dika I, Yaqubie A, Lopez J, Hwang B, El-Khoueiry A, Tang Y, Wen Y, Schwartz L, Bertagnolli M, Meyerhardt J, O'Reilly E, Venook A. *Cancer Res Commun* Feb 16. doi: 10.1158/2767-9764.CRC-22-0516. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38363156/>

## Submitted Manuscripts

**S0809** The Effect of Radiation Modality on Outcomes of Patients Receiving Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Secondary Analysis of SWOG S0809. Horowitz D, Colby S, Gholami S, Guthrie KA, Ben-Josef E, El-Khoueiry A, Blanke CD, Philip P, Chiorean E, Rocha F, Ahmad S, Kachnic L. Resubmitted 2023.

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Submitted 2023.

## Gastrointestinal Committee

**Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study**

	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806	A022001	A022102
Ascension Providence Hospitals - Southfield	-	2	-	-	3	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	4	-	2	3	-	1	-	-
Baptist Mem Health Care/Mid South MU-NCORP	-	2	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan CCC	-	-	-	-	-	-	1	-	-	-
Boston Medical Center	-	-	-	-	1	3	-	1	-	2
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	6	-	-	2	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-	-	-	-
Carle Cancer Center NCORP	1	-	-	1	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	3	-	-	-	1	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	3	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	4	-	-	1	-	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	3	17	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	2	-	1	-	-	-	-	-	-
Moffitt Cancer Center	-	-	1	-	-	4	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	9	1	-	-
Northwestern University LAPS	1	-	-	-	1	-	8	1	-	-
Ohio State U Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	1	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	2	2	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-	-

## Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806	A022001	A022102
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	2	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	3	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	2	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	4	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	2	-	1	-	-	-
U of Alabama at Birm/Deep South Res Consort LAPS	-	-	-	-	-	-	-	-	-	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	3	-	-	-
University of Colorado Cancer Center LAPS	-	2	-	3	6	-	1	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	3	-	1	-	-	2
University of Kentucky/Markey Cancer Center	-	-	3	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	3	2	1	-	-	4	-	4	-	-
University of Rochester LAPS	1	-	-	-	2	8	-	9	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	3	-	-
University of Texas MD Anderson Cancer Center LAPS	9	-	-	7	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	3	-	-	-	-	-	1	-
Vanderbilt University - Ingram Cancer Center LAPS	-	4	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	4	2	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	2	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	4	-	8	2	-	-
ALLIANCE	9	5	1	6	-	-	-	-	-	-
ECOG-ACRIN	1	9	4	6	-	-	-	-	-	-
NRG	3	4	6	7	-	-	-	-	-	-
<b>Total</b>	<b>30</b>	<b>45</b>	<b>33</b>	<b>48</b>	<b>68</b>	<b>25</b>	<b>32</b>	<b>27</b>	<b>1</b>	<b>5</b>

## Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGGI004	NRGGI005	NRGGI008
Ascension Providence Hospitals - Southfield	-	-	1	2	2	-	-	-	-	5	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South MU-NCORP	-	-	-	-	-	-	-	-	-	3	1
Baylor College of Medicine/Duncan CCC	1	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	2	2	-	2	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	2	-	3	1	3	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	3	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	1	-	-	-	1	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-	1	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	1	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	5	-	-	-	-	-	-	11	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-	1
Medical U of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	1	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	-	2	-	-	-	-	1	1
Northwestern University LAPS	-	-	1	-	1	-	-	-	-	-	-
Ohio State U Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	2	1	-	-	2	3	-	1	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-	1	-



## Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGG1004	NRGG1005	NRGG1008
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	1	-	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	5	-	-	-	-	-	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	1	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	3	1	2	-	-	-	-	1	-
USC Norris Comprehensive Cancer Center LAPS	1	1	1	-	-	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Res Consort LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	1	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	2	1	-	-	-	-	-	4
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	1	-	-	-	2	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	6	-	-	-	7	2	-	-	1	-	2
University of Texas Health Science Center at San Antonio	3	-	-	-	3	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	8	-	-	-	-	-	13	1	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	5	-	-	-	-	-	-	-	-	1	2
Virginia Mason Medical Center	2	-	-	-	-	-	-	1	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	1	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	4	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>29</b>	<b>6</b>	<b>24</b>	<b>13</b>	<b>26</b>	<b>7</b>	<b>2</b>	<b>5</b>	<b>15</b>	<b>35</b>	<b>13</b>

